Education and awareness program targeting the assessment of adherence of the treatment of dyslipidemia
Patients with dyslipidemia
18 Years +
Endpoint Classification: -
Intervention Model: -
Primary Purpose: -
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
No locations available
Receives treatment with rosuvastatin, according to International and National Guidelines on hypercholesterolemia.
Receives the same treatment as group 1 and information on health improvement, diet and exercises applied to the disease that is being treated. The positive impact of the information upon treatment will be statistically evaluated.